Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Boston Scientific Corporation (BSX) vs JPMorgan Ultra Short Income ETF (JPST) Price & Performance

Boston Scientific CorporationTrade
JPMorgan Ultra Short Income ETFTrade

Price performance (Past 24H)

Key statistics

Boston Scientific Corporation vs JPMorgan Ultra Short Income ETF — how do they compare? Boston Scientific Corporation trades at $51 (market cap $71.46B), while JPMorgan Ultra Short Income ETF trades at $50.46. Which is the better fit depends on your goals.

BSXJPST
Market Cap
$71.46B
Sector
HealthLeveraged / Inverse
52-Week High
$108.14$50.78
52-Week Low
$42.63$50.40
Enterprise Value
$83.55B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Boston Scientific Corporation

No Aura AI signal available yet.

JPMorgan Ultra Short Income ETF

JPST (JPMorgan Ultra-Short Income ETF) trades at $50.44, showing minimal daily movement with a 0.08% gain. The technical picture remains bearish with moving averages signaling caution, though the RSI suggests potential oversold conditions. Recent institutional activity shows growing interest, with Financial Management Professionals increasing their stake by 4.7% in Q2 2026. The fund maintains consistent dividend distributions of $0.17 per share, providing stable income for risk-averse investors seeking short-term bond exposure.

As an ultra-short income ETF, JPST offers conservative investors a cash-alternative with slightly higher yields than T-bills. The fund's stability and consistent dividends make it attractive for parking cash between investments or during uncertain rate environments. However, rising interest rates and inflation pressures pose headwinds for short-term bond performance. The ETF's bearish technical signals warrant monitoring, though its defensive positioning provides downside protection in volatile markets.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Boston Scientific Corporation

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Read more on BSX

About JPMorgan Ultra Short Income ETF

JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.

Read more on JPST